Abstract:Background Ki-67 is a nuclear protein involved in cell proliferation regulation, and its expression has been widely used as an index to evaluate the proliferative activity of lymphoma. However, its prognostic value for lymphoma is still contradictory and inconclusive. Methods PubMed and Web of Science databases were searched with identical strategies. The impact of Ki-67 expression on survival with lymphoma and various subtypes of lymphoma was evaluated. The relationship between Ki-67 expression and Diffuse Large B Cell Lymphoma (DLBCL) and Mantle Cell Lymphoma (MCL) was also investigated after the introduction of a CD-20 monoclonal antibody rituximab. Furthermore, we evaluated the association between Ki-67 expression and the clinical-pathological features of lymphoma. Results A total of 27 studies met the inclusion criteria, which comprised 3902 patients. Meta-analysis suggested that high Ki-67 expression was negatively associated with disease free survival (DFS) (HR = 1.727, 95% CI: 1.159-2.571) and overall survival (OS) (HR = 1.7, 95% CI: 1.44-2) for lymphoma patients. Subgroup analysis on the different subtypes of lymphoma suggested that the association between high Ki-67 expression and OS in Hodgkin Lymphoma (HR = 1.511, 95% CI: 0.524-4.358) was absent, while high Ki-67 expression was highly associated with worse OS for Non-Hodgkin Lymphoma (HR = 1.777, 95% CI: 1.463-2.159) and its various subtypes, including NK/T lymphoma (HR = 4.766, 95% CI: 1.917-11.849), DLBCL (HR = 1.457, 95% CI: 1.123-1.891) and MCL (HR = 2.48, 95% CI: 1.61-3.81). Furthermore, the pooled HRs for MCL was 1.981 (95% CI: 1.099-3.569) with rituximab and 3.123 (95% CI: 2.049-4.76) without rituximab, while for DLBCL, the combined HRs for DLBCL with and without rituximab was 1.459 (95% CI: 1.084-2.062) and 1.456 (95% CI: 0.951-2.23) respectively. In addition, there was no correlation between high Ki-67 expression and the clinical-pathological features of lymphoma including the LDH level, B symptoms, tumor stage, extranodal site, performance status and IPI score. Conclusions This study showed that the prognostic significance of Ki-67 expression varied in different subtypes of lymphoma and in DLBCL and MCL after the introduction of rituximab, which was valuable for clinical decision-making and individual prognostic evaluation.

Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation

Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

Abstract 3386: the Development of a Highly Specific Monoclonal Antibody Against Ki67 Useful for Immunohistochemistry

Preparation and Identification of Monoclonal Antibody Against Human Testis Development Related Gene 1

Production of rabbit monoclonal antibodies against mouse embryonic stem cells and identification of pluripotency-associated surface antigens.

Development of a rabbit monoclonal antibody group against Smads and immunocytochemical study of human and mouse embryonic stem cells.

Epitope analysis of antibodies recognising the cell proliferation associated nuclear antigen previously defined by the antibody Ki-67 (Ki-67 protein).

Generation and Characterisation of Rabbit Monoclonal Antibodies Against the Native Cell Surface Antigens of Embryonic Stem Cells.

Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis

Optimized Ki-67 staining in murine cells: a tool to determine cell proliferation

Production of Anti-Tumor Human Monoclonal Antibodies Using Different Approaches.

Comparison of Different Monoclonal Antibodies for the Immunohistochemical Assessment of Cell Proliferation in Routine Colorectal Biopsy Specimens.

Ki-67: more than a proliferation marker

Proliferation Markers, Proliferating Cell Nuclear Antigen, Ki67, 5-Bromo-2′-Deoxyuridine, and Cyclin D1 in Mouse Olfactory Epithelium

Expression of a Recombinant Anti-Programed Cell Death 1 Antibody in the Mammary Gland of Transgenic Mice

Production of Antitumor Human Monoclonal Antibodies by Human-Human or Mouse-Human Hybridoma

The intrinsically disorderly story of Ki-67

Expression of Exon 13 from the Ki-67 Gene in Human Cells and Tissues by Digoxigenin-Labelled Mrna in Situ Hybridization

Production of a Monoclonal Antibody for Histone H2b Isoform H2b3b

Analysis of membranous Ki-67 staining in breast cancer and surrounding breast epithelium

Preparation and Characterization of Monoclonal Antibodies Against Nucleostemin, a Protein That Controls Cell Proliferation in Stem Cells and Cancer Cells